Skip to content

Homoeopathic treatment of anxiety in adults

Double-blind, randomized, placebo-controlled trial of add-on individualized homoeopathic medicines with cognitive and behavioural therapy in improving anxiety in adults with generalized anxiety disorder

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050248
Enrollment
96
Registered
2023-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

Intervention1: Individualized homoeopathic medicines in centesimal potencies plus cognitive and behavioral therapy (CBT): Intervention is planned as administering indicated homoeopathic medicines in c
dosage and repetition depending upon the individual requirement of the cases. Patients will be advised to refrain from handling the globules or from eating, drinking, smoking or brushing teeth within

Sponsors

D N De Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients suffering from GAD (ICD code F41.1) diagnosed as per DSM-V criteria diagnosis confirmed through HAM-A (score 8-23). Initial screening for potential GAD cases will be done by using GAD-2 scoring (GAD 2 score 3 or higher) 2.Age between 18 and 65 years 3.Patients of either sex 4.Literate patients; ability to read English, Hindi and/or Bengali 5.Illiterate people will be interviewed by the investigators maintaining adequate privacy to fill up the scales or questionnaires 6.Patients undergoing any treatment for GAD included after discontinuing the same following a washout period of 15 days if the patient agreed.

Exclusion criteria

Exclusion criteria: 1.Minimal (HAM-A score 7 or less) and severe (HAM-A score 24 or more). 2.A primary psychiatric diagnosis other than GAD. 3.Suicidal tendency, pertinent current medications (anti-depressants, mood stabilizers or anti-psychotics, regular use of benzodiazepines, opioid based analgesics) 4.Three or more failed trials of pharmacotherapy for current GAD episode 5.Recently commenced psychotherapy 6.Patient unwilling to discontinue the antipsychotic or any other antidepressant medicine 7.Known clinical uncontrolled systemic disorder like uncontrolled diabetes, uncontrolled hypertension. 8.Vulnerable population- unconscious, non-ambulatory, too sick for consultation, differently abled, terminally ill or critically ill patients, mentally incompetent people. 9.Other uncontrolled or life-threatening illness affecting quality of life or any organ failure 10.Pregnant and puerperal women, lactating mothers 11.Patients with the habit of tobacco chewing and/or smoking, alcoholism and/or any other form(s) of substance abuse and/or dependence 12.Self-reported immune-compromised state 13.Already undergoing homoeopathic treatment for chronic disease within last 6 months. 14.Simultaneous participation in any other clinical trail.

Design outcomes

Primary

MeasureTime frame
Hamilton Anxiety Rating Scale (HAM-A)Timepoint: At baseline, every month, up to 3 months

Secondary

MeasureTime frame
Generalized Anxiety Disorder 7 (GAD-7) questionnaireTimepoint: At baseline, every month, up to 3 months;Hamilton Depression Rating Scale (HDRS) questionnaireTimepoint: At baseline, every month, up to 3 months;Patient Health Questionnaire (PHQ9)Timepoint: At baseline, every month, up to 3 months

Countries

India

Contacts

Public ContactArpita Basu

D. N. De Homoeopathic Medical College & Hospital

drarpitasen@gmail.com9830273374

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026